Shu Qin

Dr. Shu Qin


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
HGHaoxian Gou
Haoxian Gou
SLShenglu Liu
Shenglu Liu
LLLinxin Liu
Linxin Liu
MLMing Luo
Ming Luo
SQShu Qin
Shu Qin
XYXiaoli Yang
Xiaoli Yang
Hepatocellular carcinoma (HCC) is the most common type of liver malignancy with a high incidence and mortality rate. Previous in vitro and in vivo studies have confirmed that liver sinusoidal endothelial cells (LSEC) secrete CXCL16, which acts as a messenger to increase the hepatic accumulation of CXCR6+ natural killer T (NKT) cells and exert potent antitumor effects. However, evidence for this process in humans is lacking and its clinical significance is still unclear. In this study, by dissecting the human HCC single-cell RNA-seq data, we verified this process through cellphoneDB. NKT cells in patients with high expression of CXCL16 exhibited a higher activation state and produced more interferon-γ (IFN-γ) compared with those with low expression. We next investigated the signaling pathways between activated (CD69 high) and unactivated NKT cells (CD69 low) using NKT cell-developmental trajectories and functional enrichment analyses. In vivo experiments, we found that farnesoid X receptor agonist (obeticholic acid) combined with the takeda G protein coupled receptor 5 antagonist (5β-cholanic acid 3) exhibited significant tumor suppressive effects in the orthotopic liver tumor model and this result may be related to the CXCL16/CXCR6 axis. In conclusion, our study provides the basis and potential strategies for HCC immunotherapy based on NKT cells.

2 July 2019 in Mediators of Inflammation
Verified
Journal Article
Open access
ZZZhenyu Zhou
Zhenyu Zhou
YCYu Chen
Yu Chen
DZDongying Zhang
Dongying Zhang
SWShiyong Wu
Shiyong Wu
TLTao Liu
Tao Liu
SQShu Qin
Shu Qin
Atherosclerosis is one of the leading causes of mortality worldwide. Growing evidence suggested that miRNAs contributed to the progression of atherosclerosis. miR-30-5p was found involved in various diseases. However, the role of miR-30-5p in regulation of atherosclerosis is not known. Here, we aim to investigate the effects of miR-30-5p on regulating the progression of atherosclerosis. The expression levels of miR-30-5p in serum collected from atherosclerosis patients and normal healthy people were analyzed by qRT-PCR. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway bioinformatics were carried out to reveal the possible signaling pathways involved in the mode of action of miR-30-5p. A potential target gene of miRNA-30-5p was searched and examined by a luciferase reporter assay. ELISA, Western blot, proliferation, and flow cytometry assays were performed to assess the biological functional role of miR-30-5p in vitro. Also, an in vitro monocyte-endothelial cell coculture model was used to study the functional role of miR-30-5p in atherosclerosis. We found that miR-30-5p was significantly decreased in serum samples from atherosclerosis patients compared with control subjects. GO and KEGG analysis results showed that miR-30-5p is highly associated with genetic profile of cardiovascular disease. TCF21 was verified as a target gene of miR-30-5p. Overexpression of miR-30-5p in THP-1 not only protected endothelial cell viability but also inhibited endothelial cell apoptosis, and similar results were observed in cells with that of TCF21 knocked down. Moreover, miR-30-5p decreased the expression levels of lactate dehydrogenase (LDH) and tumor necrosis factor-α (TNF-α) and reduced reactive oxygen species (ROS) accumulation. NF-κB and MAPK/p38 pathways played an indispensable role in the protection ability of miR-30-5p against atherosclerosis. Our results reveal that miR-30-5p suppresses the progression of atherosclerosis through targeting TCF21 in vitro. Therefore, the miR-30-5p-TCF21-MAPK/p38 signaling pathway may be a potential biomarker or therapeutic target in atherosclerosis.

10 May 2023 in Food Chemistry: X
Verified
Journal Article
Open access
MWMin Wang
Min Wang
LZLuyao Zhao
Luyao Zhao
YNYu Niu
Yu Niu
SQShu Qin
Shu Qin
LZLixin Zhang
Lixin Zhang
XJXu Jing
Xu Jing
• Novel DESs were prepared as green extraction solvents. • No toxic dispersion solvents were used. • Phase separation time was reduced by the external magnetic field. • Hydrophobic DESs were applied for aqueous samples. • The proposed microextraction method was rapid and green.

1 January 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
PZPeng Zhang
Peng Zhang
XXXin Xing
Xin Xing
CHChunxiao Hu
Chunxiao Hu
HYHui Yu
Hui Yu
QDQian Dong
Qian Dong
DZDongying Zhang
Dongying Zhang
Statins exert pleiotropic effects on endothelial cells in addition to lowering cholesterol. 15-Lipoxygenase-1 (ALOX15) has been implicated in vascular inflammation and disease. The relationship between atorvastatin and ALOX15 was investigated using a rat carotid artery balloon-injury model. Hematoxylin and eosin (HE) staining showed that ALOX15 overexpression increased the thickness of the intima-media (IMT). Immunohistochemistry and western blotting showed that atorvastatin increased the expression of cellular adhesion molecules (CAMs) but decreased the expression of endothelial nitric oxide synthase (eNOS); these effects of atorvastatin were blocked by ALOX15 overexpression. In human umbilical venous endothelial cells (HUVECs), silencing of ALOX15 enhanced the effects of atorvastatin on endothelial function. Expression levels of CAMs and Akt/eNOS/NO under oxidized low-density lipoprotein (ox-LDL) stimulation were modulated by ALOX15 inhibitor and ALOX15 small interfering RNA (siRNA). Atorvastatin abolished the activation of nuclear factor-kappa B (NF-κB) induced by ox-LDL. Exposure to ox-LDL induced upregulation of ALOX15 in HUVECs, but this effect was partially abolished by atorvastatin or the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC). These results demonstrate that regulation of ALOX15 expression might be involved in the effects of atorvastatin on endothelial dysfunction.

22 October 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
ZZZhen-Yu Zhou
Zhen-Yu Zhou
YCYu Chen
Yu Chen
DZDongying Zhang
Dongying Zhang
SWShiyong Wu
Shiyong Wu
TLTao Liu
Tao Liu
SQShu Qin
Shu Qin
[This corrects the article DOI: 10.1155/2019/1342190.].